Cannabix Technologies Inc. announced that it has completed preliminary third-party testing on its Contactless Alcohol Breathalyzer wall mounted device. The Company is nearing completion of its first commercial version of its CAB device and has conducted electronics testing in October at QAI Laboratories ("QAI") in British Columbia, an accredited lab recognized in the U.S and Canada for its electrical safety evaluations and certification. In particular, engineers successfully completed preliminary electromagnetic compatibility (EMC), emissions, immunity testing and vibration testing at QAI with the Cannabix CAB device.

The CAB workplace series (industrial version) is now being prepared for international alcohol standards testing. New CAB Workplace Series (Industrial version) The Company is completing its first CAB technology for workplaces, an industrial weather resistant version with many features including an innovative pre-calibrated modular cartridge technology. Cannabix commenced pilot testing of its work series CAB with the Montana based, Friedel Clinic, in March 2023 and the device has performed well with over 700 breath samples taken thus far.

The CAB device is part of the Company's portfolio of marijuana and alcohol screening devices. The Company will be selecting a new product name for the CAB and create new product branding in the coming weeks. Cannabix is covering two significant threats to workplace safety with its alcohol and marijuana breath screening technologies.

An increasing number of employers are taking proactive measures to safeguard their workers and their operations by implementing alcohol testing procedures. Cannabix will be targeting the CAB for small to medium sized enterprises (SME's), in a range of industries like construction, production, oil and gas, mining, agriculture, forestry sectors and warehousing and transport industry. 24/7 Sobriety Program in the United States.

More recently the Company has been examining the use of the CAB as a new solution for the 24/7obriety Program existing in several states in the U.S. This program seeks to reduce the re-arrests of individuals previously convicted of driving while under the influence (DUI) of alcohol or drugs through daily breath testing. A robust feature set for the CAB includes contactless and direct breath testing, photo identity confirmation, time and attendance, Wi-Fi connectivity, RFID log-in. A live data management portal for managers seeking real-time BAC results via the text and email has been developed.

This data management system uses best in class Amazon Web Services (AWS) for its cloud-based infrastructure and security. New Innovation - CAB Pre-Calibrated Alcohol Sensor Cartridges. The Company has developed an innovative pre-calibrate modular cartridge technology that will allow organizations to quickly and easily maintain their CAB devices.

This new technology holds the potential to transform a host of existing technologies which reply upon costly calibration equipment and time-consuming site visits from technicians for maintenance. The Cannabix cartridge technology provides a way for customers and distributors to replace cartridges to maintain calibration. This press release contains forward-looking information that involves various risks and uncertainties regarding future events.

Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company To develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that any proposed new products will be successful in beta testing or clinical trials.

The is no assurance that the Company will be successful in beta testing and clinical trials. The is No assurance that the Company will enter into any partnerships to advance any partnerships to advance any partnerships of its corporate initiatives or technologies. The Company will enter into any partnerships.

The company will enter into any partnership to advance any of its corporate initiatives or clinical trials.